A Study of Quetiapine SR (Seroquel SR) to Treat SSRI-Resistant, Comorbid Panic Disorder Patients
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to test the hypothesis that a SSRI plus quetiapine SR
(Seroquel SR) will result in superior early (first 1-3 weeks of treatment) stabilization of
panic symptoms in SSRI-resistant, comorbid Panic Disorder patients versus a SSRI plus
placebo.